PORT WASHINGTON, N.Y., Dec. 11, 2012 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, launched the first generic version of the 500 mg strength (microsize) of Griseofulvin Tablets USP, an FDA approved generic version of Valeant Pharmaceutical’s Grifulvin V®. According to IMS Health data, U.S. market sales for Griseofulvin tablets, an antifungal antibiotic that fights infections caused by fungus, were approximately $13 million for the twelve months ended June 30, 2012. The launch of the 500 mg strength of Griseofulvin tablets USP follows the previously announced launch of the first generic version of the 125mg and 250mg strengths of Ultramicrosize Griseofulvin tablets USP by Rising Pharmaceuticals in November 2012.
